About: http://data.cimple.eu/news-article/e5126b71883657ef582b415c625bda27c192ce0e3737f49c85455f32

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/e5126b71883657ef582b415c625bda27c192ce0e3737f49c85455f32 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Ireland will limit the AstraZeneca coronavirus jab to those aged over 60, the country's chief medical officer said Monday, following European reviews of evidence linking it to rare blood clotting cases. The decision follows similar moves by several other European nations that have halted use of the vaccine among younger people following the EU medicines regulator's ruling this month that it could be linked to the rare clots. Ireland's National Immunisation Advisory Committee (NIAC) said the AstraZeneca product "is not recommended for those aged under 60 years". The updated recommendations would be incorporated into the vaccination programme and vaccine re-allocated, chief medical officer Ronan Glynn said. Ireland, which has a population of around five million, has so far given nearly 750,000 people a first Covid-19 vaccine dose, according to the latest available statistics. Along with other EU countries, it has struggled to match the speed of neighbouring Britain's successful rollout, which has relied heavily on the AstraZeneca jab. UK regulators have only limited its use in the under-30s. NIAC chair Karina Butler noted that the shot, which was developed in partnership with Britain's Oxford University, was "highly effective and substantially reduces the risk of severe COVID-19 disease across all age groups". But the committee had opted to change its advice in light of the reviews. "NIAC realises the need to balance the significant benefits of a national vaccination programme with the very rare risk of these reported events," she said in a statement. "While this is an extremely rare condition, consideration must be given to the fact that it has a very high risk of death or severe outcome. "As the risk/benefits of Vaxzevria COVID-19 AstraZeneca vaccine may vary by age, and as alternative COVID-19 vaccines are available, NIAC has revised the recommendations for use of this vaccine," she added. jts/jj/bp
schema:headline	Ireland to limit AZ jab to over-60s
schema:mentions	Butler Carib language Thrombosis Republic of Ireland Jab University of Oxford AstraZeneca Arizona European Union United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 National Iranian American Council Glynn
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-12 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	83 (xsd:integer)

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software